Avoro Capital Advisors ARWR Position
Active8-Fund ConvergenceAvoro Capital Advisors trimmed their position in Arrowhead Pharmaceuticals Inc. (ARWR) in Q4 2025, holding $705.4M worth of shares across 10,625,000 shares.
The position was first reported in Q2 2023 and has been tracked across 11 quarterly 13F filings.
ARWR is a convergence signal: 8 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for Plozasiran Injection in 45 days (May 31, 2026), making the timing of Avoro Capital's position particularly relevant.
Short interest stands at 11.4% of float with 5.1 days to cover, indicating significant bearish positioning against Avoro Capital's long thesis.
About Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Full company profile →Short Interest
11.4%
5.1 days to cover
Avoro Capital Advisors ARWR Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Decreased | 10,625,000 | -275,000 | $705.4M |
| Q3 2025 | Increased | 10,900,000 | +300,000 | $375.9M |
| Q2 2025 | Decreased | 10,600,000 | -511,111 | $167.5M |
| Q1 2025 | Held | 11,111,111 | — | $141.6M |
| Q4 2024 | Increased | 11,111,111 | +2,222,223 | $208.9M |
| Q3 2024 | Held | 8,888,888 | — | $172.2M |
| Q2 2024 | Increased | 8,888,888 | +333,333 | $231.0M |
| Q1 2024 | Increased | 8,555,555 | +7,425,555 | $244.7M |
| Q4 2023 | Increased | 1,130,000 | +565,000 | $34.6M |
| Q3 2023 | Increased | 565,000 | +207,597 | $15.2M |
| Q2 2023 | New | 357,403 | +357,403 | $12.7M |
Frequently Asked Questions
Does Avoro Capital Advisors own ARWR?
Yes. As of Q4 2025, Avoro Capital Advisors holds 10,625,000 shares of Arrowhead Pharmaceuticals Inc. (ARWR) valued at $705.4M. This data comes from their SEC 13F filing.
How many hedge funds own ARWR?
8 specialist biotech hedge funds currently hold ARWR, including Baker Bros. Advisors, Deerfield Management, Driehaus Capital and 4 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Avoro Capital Advisors first buy ARWR?
Avoro Capital Advisors's position in ARWR was first reported in Q2 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Avoro Capital Advisors's ARWR position increasing or decreasing?
Avoro Capital Advisors trimmed their ARWR position in the most recent quarter, reducing by 275,000 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ARWRCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Avoro Capital AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →